Conference
Safety and antitumor activity of selinexor (KPT-330), a first-in-class, oral XPO1 selective inhibitor of nuclear export: A phase I study expanded with colon cancer cohort.
Abstract
482
Authors
Mau-Soerensen M; Razak ARA; Mahipal A; Mahaseth H; Gerecitano JF; Shacham S; Yau CYF; Lassen U; Shields AF; McCauley D
Volume
32
Pagination
pp. 482-482
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
January 20, 2014
DOI
10.1200/jco.2014.32.3_suppl.482
Conference proceedings
Journal of Clinical Oncology
Issue
3_suppl
ISSN
0732-183X